Secondaries announced 10.17.2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating.

Company: Nektar Therapeutics
Symbol: NKTR
Price: Last trade $15.67
Trade Date: 10/19
Shares: 11.2 million
Underwriter(s)J.P. Morgan
Rating=Subscription Needed